Bristol Myers touts PhIII Opdivo win in urothelial carcinoma; Liminal BioSciences goes private
Bristol Myers Squibb said Tuesday that a sub-study of a Phase III trial testing Opdivo with cisplatin-based chemotherapy, followed by Opdivo monotherapy, met the primary …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
